Price
$6.03
Decreased by -0.99%
Dollar volume (20D)
113.61 M
ADR%
10.16
Earnings report date
Feb 25, 2025
Shares float
252.42 M
Shares short
67.85 M [26.88%]
Shares outstanding
383.72 M
Market cap
2.38 B
Beta
0.80
Price/earnings
N/A
20D range
5.60 9.55
50D range
5.60 9.55
200D range
5.60 12.35

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery.

The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer.

The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited.

Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
Nov 6, 24 -0.34
Increased by +20.93%
-0.35
Increased by +2.86%
Aug 8, 24 -0.40
Decreased by -5.26%
-0.40
May 9, 24 -0.39
Decreased by -14.71%
-0.42
Increased by +7.14%
Feb 27, 24 -0.42
Decreased by -35.48%
-0.45
Increased by +6.67%
Nov 9, 23 -0.43
Decreased by -22.86%
-0.38
Decreased by -13.16%
Aug 8, 23 -0.38
Increased by 0.00%
-0.37
Decreased by -2.70%
May 8, 23 -0.34
Decreased by -3.03%
-0.35
Increased by +2.86%
Feb 27, 23 -0.31
Increased by +18.42%
-0.29
Decreased by -6.90%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 24 26.08 M
Increased by +158.19%
-95.67 M
Decreased by -2.86%
Decreased by -366.82%
Increased by +60.16%
Jun 30, 24 14.42 M
Increased by +30.87%
-97.54 M
Decreased by -27.13%
Decreased by -676.56%
Increased by +2.86%
Mar 31, 24 13.79 M
Increased by +13.68%
-91.37 M
Decreased by -50.31%
Decreased by -662.41%
Decreased by -32.22%
Dec 31, 23 10.89 M
Decreased by -20.36%
-93.00 M
Decreased by -61.79%
Decreased by -853.88%
Decreased by -103.16%
Sep 30, 23 10.10 M
Decreased by -22.61%
-93.02 M
Decreased by -59.50%
Decreased by -920.78%
Decreased by -106.10%
Jun 30, 23 11.02 M
Increased by +43.94%
-76.73 M
Decreased by -17.06%
Decreased by -696.50%
Increased by +18.68%
Mar 31, 23 12.13 M
Increased by +128.99%
-60.79 M
Decreased by -8.60%
Decreased by -500.98%
Increased by +52.58%
Dec 31, 22 13.68 M
Increased by +447.04%
-57.48 M
Increased by +11.48%
Decreased by -420.29%
Increased by +83.82%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY